Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS

Bibliography

• The AIDS Institute Global Fact Sheet. Available from: http://www.theaidsinstitute.org/sites/default/files/attachments/THE%20AIDS%20INSTITUTE%20Global%20Fact%20Sheet.pdf
   Google Scholar
• Richman DD, Margolis DM, Delaney M, The challenge of finding a cure for HIV infection. Science 2009;323:1304-7
   PubMed Web of Science ®Google Scholar
• Howell AL, Asin SN, Yeaman GR, Wira CR. HIV-1 infection of the female reproductive tract. Curr HIV/AIDS Rep 2005;2:35-8
   PubMedGoogle Scholar
• Gurney KB, Elliott J, Nassanian H, Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol 2005;79:5762-73
   PubMed Web of Science ®Google Scholar
• Kreiss J, Ngugi E, Holmes K, Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-82
   PubMed Web of Science ®Google Scholar
• Roddy RE, Zekeng L, Ryan KA, A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998;339:504-10
   PubMed Web of Science ®Google Scholar
• Richardson BA, Lavreys L, Martin HL Jr, Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001;8:394-400
   Web of Science ®Google Scholar
• Van Damme L, Ramjee G, Alary M, COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360:971-7
   PubMed Web of Science ®Google Scholar
• Peterson L, Nanda K, Opoku BK, SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo controlled trial in Ghana. PLoS ONE 2007;2:e1312
   PubMed Web of Science ®Google Scholar
• Feldblum PJ, Adeiga A, Bakare R, SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008;3:e1474
   PubMed Web of Science ®Google Scholar
• Halpern V, Ogunsola F, Obunge O, Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 2008;3:e3784
   PubMed Web of Science ®Google Scholar
• Van Damme L, Govinden R, Mirembe F, CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72
   PubMed Web of Science ®Google Scholar
• Family Health International (FHI). FHI closes phase III trial of cellulose sulfate for HIV prevention; Research Triangle Park, NC: FHI, January 31, 2007. Available from: http://www.fhi.org/en/AboutFHI/Media/Releases/res_CS_Nigeria.htm
   Google Scholar
• CONRAD. Phase III trials of cellulose sulfate microbicide for HIV prevention closed [press release]. 2007. Available from: http://www.medi calnewstoday.com/articles/62310.php
   Google Scholar
• Skoler-Karpoff S, Ramjee G, Ahmed K, Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-87
   PubMed Web of Science ®Google Scholar
• McCormack S, Ramjee G, Kamali A, PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase III, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329-37
   PubMed Web of Science ®Google Scholar
• Abdool Karim S, Coletti A, Richardson B, HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. AIDS 2011;25:957-66
   PubMed Web of Science ®Google Scholar
• Perelson AS, Neumann AU, Markowitz M, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6
   PubMed Web of Science ®Google Scholar
• Cohen MS, Hosseinipour M, Kashuba AD, Butera S. Use of antiretroviral drugs to prevent sexual transmission of HIV. In: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Diseases. Volume 22 Blackwell Science; Cambridge, MA: 2002. p. 214-51
   Google Scholar
• AVERT (AIDS Education & Research Trust). Post exposure prophylaxis and pre-exposure prophylaxis. Available from: http://www.avert.org/pep-prep-hiv.htm
   Google Scholar
• CDC. Pre-exposure prophyxaxis (PrEP), February 21, 2011. Available from: http://www.cdc.gov/hiv/prep/
   Google Scholar
• AIDS Vaccine Advocacy Coalition. Global advocacy for HIV prevention. Ongoing PrEP trials. Available from: http://www.avac.org/ht/d/sp/i/3507/pid/3507
   Google Scholar
• Naswa S, Marfatia YS. Pre-exposure prophylaxis of HIV. Indian J Sex Transm Dis 2011;32:1-8
   PubMedGoogle Scholar
• Mayer KH, Venkatesh KK. Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr 2010;55(Suppl 2):S122-7
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci 2010;31:74-81
   PubMed Web of Science ®Google Scholar
• Lampe MA, Smith DK, Anderson GJ, Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488; e1-8
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 2011;8:94-103
   PubMedGoogle Scholar
• De Clercq E. Pre-exposure chemoprophylaxis of HIV infection: quo vadis? Biochem Pharmacol 2012;83:567-73
   PubMed Web of Science ®Google Scholar
• Tsai C-C, Follis KE, Sabo A, Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-8
   PubMed Web of Science ®Google Scholar
• Subbarao S, Otten RA, Ramos A, Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-11
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Kearney BP, Sexton JJ, Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006;43:6-14
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma JG, Otten RA, Qari SH, Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5:e28
   PubMed Web of Science ®Google Scholar
• Denton PW, Estes JD, Sun Z, Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5:e16
   PubMed Web of Science ®Google Scholar
• Denton PW, Krisko JF, Powell DA, Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010;5:e8829
   PubMed Web of Science ®Google Scholar
• Neff CP, Ndolo T, Tandon A, Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010;5:e15257
   PubMed Web of Science ®Google Scholar
• CDC Update: TDF2 study of pre-exposure prophylaxis (PrEP) among heterosexual men and women in Botswana: key facts. Available from: http://www.cdc.gov/hiv/prep/pdf/TDF2factsheet.pdf
   Google Scholar
• University of Washington Partners PrEP Study update: Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. July 13, 2011. Available from: http://depts.washington.edu/astda/resources/PrEP_PressRelease-UW_13Jul2011.pdf
   Google Scholar
• Baeten J, Celum C. on behalf of the Partners PrEP Study Team. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study [abstract MOAX0106]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy; 2011
   Google Scholar
• Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 2012;25:51-7
   PubMed Web of Science ®Google Scholar
• CDC. Results of FEM-PrEP clinical trial examining pre-exposure prophylaxis (PrEP) for HIV prevention among heterosexual women (April 18, 2011). Available from: http://www.cdc.gov/hiv/prep/femprep.htm
   Google Scholar
• FHI 360: FEM-PrEP June 2011 Update: FEM-PrEP study will be highly unlikely to demonstrate Truvada's effectiveness in preventing HIV infection in the study population. Available from: http://www.fhi360.org/NR/rdonlyres/erj6hevouwvddigjldvcca6tvtybfolh4nedyfeo4yz2i7la53jknim6ex42bme2rvyq6zfzovyrkb/FEMPrEPFactSheetJune2011.pdf
   Google Scholar
• Grant RM, Lama JR, Anderson PL, iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99
   PubMed Web of Science ®Google Scholar
• IAS 2011: Final iPrEX analysis confirms PrEP effectiveness for gay men; 29 July 2011. Available from: http://www.hivandhepatitis.com/hiv-prevention/hiv-prep/3113-ias-2011-final-iprex-analysis-confirms-prep-effectiveness
   Google Scholar
• Liegler T, Abdel-Mohsen M, Atchison R. and iPrEx Study Team. Drug resistance and minor drug resistant variants in iPrEx [abstract 97LB]. 18th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA; 2011
   Google Scholar
• Anderson PL, Kiser JJ, Gardner EM, Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011;66:240-50
   PubMed Web of Science ®Google Scholar
• Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71
   PubMed Web of Science ®Google Scholar
• Jhaveri MA, Mawad HW, Thornton AC, Tenofovir-associated severe bone pain: i cannot walk! J Int Assoc Physicians AIDS Care. 2010;9:328-34
   Google Scholar
• Vigano A, Zuccotti GV, Martelli L, Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007;27:573-81
   PubMed Web of Science ®Google Scholar
• Calmy A, Fux CA, Norris R, Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009;200:1746-54
   PubMed Web of Science ®Google Scholar
• Kohler JJ, Hosseini SH, Green E, Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011;91:852-8
   PubMed Web of Science ®Google Scholar
• Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011;53:1265-70
   PubMed Web of Science ®Google Scholar
• Wolf K, Walter H, Beerenwinkel N, Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003;47:3478-84
   PubMed Web of Science ®Google Scholar
• Cheung PK, Wynhoven B, Harrigan PR. Which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004;6:107-16
   PubMed Web of Science ®Google Scholar
• White KL, Chen JM, Margot NA, Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004;48:992-1003
   PubMed Web of Science ®Google Scholar
• Das K, Bandwar RP, White KL, Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 2009;284:35092-100
   PubMed Web of Science ®Google Scholar
• Sigal A, Kim JT, Balazs AB, Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011;477:95-8
   PubMed Web of Science ®Google Scholar
• Dolling D, Phillips A, Delpech V, on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (UK CHIC) Study. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med 2011; doi: 10.1111/j.1468-1293.2011.00968.x.
   PubMed Web of Science ®Google Scholar
• Hachiya A, Kodama EN, Schuckmann MM, K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 2011;6:e16242
   PubMed Web of Science ®Google Scholar
• Microbicide Trials Network. MTN-003 Available from: http://www.mtnstopshiv.org/about/hiv_aids
   Google Scholar
• NIH News: NIH discontinues Tenofovir vaginal gel in 'VOICE' HIV prevention study. November 25, 2011. Available from: http://www.nih.gov/news/health/nov2011/niaid-25.htm
   Google Scholar
• NIH News: NIH Modifies ‘VOICE’ HIV prevention study in women: Oral Tenofovir discontinued in clinical trial. Available from: http://www.niaid.nih.gov/news/newsreleases/2011/Pages/VOICEmodified.aspx
   Google Scholar
• Patterson KB, Prince HA, Kraft E, Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3:112re4
   PubMed Web of Science ®Google Scholar
• Vig R, Venkatachalam TK, Uckun FM. D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. Antivir Chem Chemother 1998;9:445-8
   PubMed Web of Science ®Google Scholar
• Uckun FM, Pendergrass S, Venkatachalam TK, Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 2002;46:3613-16
   PubMed Web of Science ®Google Scholar
• Venkatachalam TK, Tai HL, Vig R, Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg Med Chem Lett 1998;8:3121-6
   PubMed Web of Science ®Google Scholar
• Zhang H, Dornadula G, Beumont M, Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998;339:1803-9
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Venkatachalam TK, Uckun FM. Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm. Biol Reprod 2001;64:51-9
   PubMed Web of Science ®Google Scholar
• Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:13-23
   PubMed Web of Science ®Google Scholar
• Paraskevis D, Pybus O, Magiorkinis G, SPREAD Programme. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology 2009;6:49
   PubMed Web of Science ®Google Scholar
• Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK. In vitro activity of stampidine against primary clinical HIV isolates. Arzneimittelforschung 2004;54:69-77
   PubMed Web of Science ®Google Scholar
• Uckun FM, Venkatachalam TK, Qazi S. Potency of Stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittelforschung 2006;56:193-203
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Uckun FM. Microbicides for multidrug-resistant and multitropic HIV-1. [Review]. Curr Opin Investig Drugs 2008;9(2):152-69
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Venkatachalam TK. In vitro anti-HIV potency of Stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 2005;55:223-31
   PubMed Web of Science ®Google Scholar
• Peeters M, Esu-Williams E, Vergne L, Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000;16:315-25
   PubMed Web of Science ®Google Scholar
• Yirrell DL, Kaleebu P, Morgan D, Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS 2002;16:279-86
   PubMed Web of Science ®Google Scholar
• Steain MC, Wang B, Dwyer DE, Saksena NK. HIV-1 co-infection, superinfection and recombination. Sex Health 2004;1:239-50
   PubMedGoogle Scholar
• Brenner B, Routy JP, Quan Y, Co-Investigators of the Quebec Primary Infection Study. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004;18:1653-60
   PubMed Web of Science ®Google Scholar
• Smith DM, Wong JK, Hightower GK, HIV drug resistance acquired through superinfection. AIDS 2005;19:1251-6
   PubMed Web of Science ®Google Scholar
• Smith DM, Strain MC, Frost SD, Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006;355:1-5
   PubMed Web of Science ®Google Scholar
• Campbell MS, Gottlieb GS, Hawes SE, HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One 2009;4:e5690
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Basar A, Gazzard BG. Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy. AIDS 2000;14:1292-3
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Wildfire A, Mandalia S, Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72
   PubMed Web of Science ®Google Scholar
• Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis 2002;34:1108-14
   PubMed Web of Science ®Google Scholar
• Uckun FM. Unmet challenges in HIV therapy and potential of stampidine. Arzneimittelforschung 2006;56:117-20
   PubMed Web of Science ®Google Scholar
• Uckun FM. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Arzneimittelforschung 2006;56:121-35
   PubMed Web of Science ®Google Scholar
• Chen CL, Venkatachalam TK, Zhu ZH, Uckun FM. In vivo pharmacokinetics and metabolism of anti-HIV agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] in mice. Drug Metab Dispos 2001;29:1035-41
   PubMed Web of Science ®Google Scholar
• Chen CL, Yu G, Venkatachalam T, Uckun FM. Metabolism of stavudine-5'-[p-bromophenyl methoxy alaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 2002;30:1523-31
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Pendergrass S, In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5'-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 2002;46:3428-36
   PubMed Web of Science ®Google Scholar
• Uckun FM, Chen CL, Lisowski E, Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittelforschung 2003;53:357-67
   PubMed Web of Science ®Google Scholar
• Uckun FM, Waurzyniak B, Tibbles H, In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung 2006;56:176-92
   PubMed Web of Science ®Google Scholar
• Uckun FM, Chen CL, Samuel P, In vivo antiretroviral activity of stampidine in chronically FIV-infected cats. Antimicrob Agents Chemother 2003;47:1233-40
   PubMed Web of Science ®Google Scholar
• D'Cruz OJ, Erbeck D, Uckun FM. Developmental safety profile of the anti-HIV agent stampidine in rabbits. Arzneimittelforschung 2006;56:159-66
   PubMed Web of Science ®Google Scholar
• DuMez D, Venkatachalam TK, Uckun FM. Large-scale synthesis and formulation of GMP-grade stampidine, a new anti-HIV agent. Arzneimittelforschung 2006;56:136-51
   PubMed Web of Science ®Google Scholar
• Uckun FM, DuMez D, Qazi S, Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 2007;57:112-21
   PubMed Web of Science ®Google Scholar
• Cahn P, Rolon MJ, Gun AM, Preclinical and first-in-human phase I clinical evaluation of stampidine, a potent anti-HIV pharmaceutical drug candidate. J AIDS Clin Res 2012;3:1 In press
   Google Scholar